Drug intelligence / Profile preview

Shenyan Kangfu Tablet

Development stage: Phase 4
Lead developer: Tianjin Tongrentang Group
Modality: Small Molecules
Administration: Oral

Overview

Shenyan Kangfu Tablet (SYKFT) is a Chinese patent medicine derived from traditional Chinese herbal formulations. It was originally designed for treating chronic nephritis patients diagnosed with qi-yin deficiency syndrome (characterized by lack of qi and yin energy in the body). SYKFT works primarily by inhibiting NF-κB signaling pathways to reduce renal inflammation and by modulating gut microbiota composition. Clinical evidence shows it can reduce blood glucose and HbA1c levels, alleviate renal dysfunction, and reduce glomerular and tubular damage in diabetic kidney disease.

Brand names: Shenyan Kangfu Tablet
Other names: Nephritis recovery tablets

Targets

NF-κB

Beyond the preview

Go deeper on Shenyan Kangfu Tablet.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenyan Kangfu Tablet.

Explore the full profile